JPRN-UMIN000032147已完成1 期
A clinical study on the safety of immune-cell therapy combined with standard therapy for high-grade glioma - A clinical study on the safety of immune-cell therapy combined with standard therapy for high-grade glioma
Juntendo University Faculty of Medicine0 个研究点目标入组 5 人开始时间: 2018年4月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Be apparent from the clinical manifestation of pulmonary fibrosis or interstitial pneumonia 2)Have a history of a serious drug allergy 3)Have a positive result of HIV or HTLV-1 antibody test 4)Have a serious cardiac disorder 5)Have an active autoimmune disorder 6)Have a cancer other than glioma 7)Have an infectious disorder that is difficult to control 8)Be a female who is pregnant
研究者
相似试验
招募中
1 期
evaluate the safety and immunomodulatory efficacy of Byolic CC supplementImmunomodulatory effect on healthy volunteers.IRCT20240304061158N4Behpad Teb Iranian90
Unknown
3 期
A clinical trial to study immunogenicity and safety of Purified Chick Embryo Cell Culture Rabies Vaccine administered intradermallyCTRI/2010/091/000509Cadila Healthcare Ltd36
已完成
4 期
Protection and Safety of rabies vaccine when administered intradermallyCTRI/2012/06/002720I70
进行中（未招募）
1 期
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers when Administered Concomitantly with Routine Pediatric Vaccines in the UK.EUCTR2017-004520-30-GBSanofi Pasteur700
进行中（未招募）
1 期
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine when co-administered with Routine Pediatric Vaccines in Healthy Infants and Toddlers in EuropeHealthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W)MedDRA version: 20.0Level: PTClassification code 10027274Term: Meningococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-004731-36-ITSanofi Pasteur Inc.1,540